The Vetr crowd on Monday upgraded their rating for Sarepta Therapeutics Inc SRPT from 1.5 stars (Strong Sell), issued eight days ago, to 3 stars (Hold). At the time of the upgrade, crowd sentiment for Sarepta was mostly positive, with 88 percent of Vetr user ratings bullish.
Share price in Sarepta has been trending up since the company reported its earnings at the end of February. The pharmaceutical company exceeded both analyst estimates for EPS and revenue, the former by over 45 percent and the latter by nearly $400,000.
In the wake of the positive report, Sarepta received an initiation at Buy from analysts at Nomura and the stock has posted gains of nearly 10 percent.
Learn how crowdsourced ratings could help you time the market.
Currently, The Vetr crowd's average target price for Sarepta is up at 34.40, which is still well below the average anlyst target price of $65.24. Less than 2% of Vetr users are holding SRPT in their watch lists.
© 2024 Benzinga.com. Benzinga does not provide investment advice. All rights reserved.
date | ticker | name | Price Target | Upside/Downside | Recommendation | Firm |
|---|
Trade confidently with insights and alerts from analyst ratings, free reports and breaking news that affects the stocks you care about.
